BridgeBio Oncology SPAC merger S-4 effective; shareholder vote set for Aug 4, 2025

BridgeBio Oncology Therapeutics, Inc.

SEC declared Registration Statement on Form S-4 effective for Helix/BBOT business combination.
Extraordinary General Meeting of Helix shareholders scheduled for August 4, 2025.
Record date for shareholders entitled to vote is June 30, 2025.
Business combination expected to close in August 2025, subject to conditions.
Post-close company will be renamed BridgeBio Oncology Therapeutics.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.